{"claims": [{"text": "In a 2-year prospective cohort of 517 patients receiving stable long-term opioid therapy for musculoskeletal pain, 19.5% underwent dose escalation, but escalation was not associated with improved pain outcomes.", "quote_or_locator": "Introduction, paragraph 1: 'In a 2-year prospective cohort of 517 patients receiving stable long-term opioid therapy for musculoskeletal pain, 19.5% underwent dose escalation, but escalation was not associated with improved pain outcomes (Morasco et al., 2020).'"}, {"text": "BV-2 microglial cells were treated with morphine at 200 micromolar with or without zonisamide at 10 micromolar for 12 hours.", "quote_or_locator": "Results section 2.1: 'BV-2 cells were treated with morphine (200 μM) in the presence or absence of zonisamide (10 μM) for 12 h.'"}, {"text": "Morphine exposure significantly upregulated the mRNA levels of IL-1β, IL-6, and TNF-α, which zonisamide co-treatment markedly suppressed.", "quote_or_locator": "Results section 2.1: 'Morphine exposure significantly upregulated the mRNA levels of IL-1β, IL-6, and TNF-α, as determined by real-time quantitative PCR. Zonisamide co-treatment markedly suppressed the elevated mRNA expression levels of these pro-inflammatory cytokines (Figures 1A–C).'"}, {"text": "Zonisamide also significantly reduced morphine-induced protein levels of pro-inflammatory cytokines at the translational level.", "quote_or_locator": "Results section 2.1: 'ELISA analysis revealed that zonisamide also significantly reduced morphine-induced protein levels of these pro-inflammatory cytokines (Figures 1D–F), confirming that the anti-inflammatory effect of zonisamide occurs at both the transcriptional and translational levels.'"}, {"text": "Morphine upregulated TLR4 mRNA expression and increased p38 MAPK phosphorylation, both of which were significantly attenuated by zonisamide co-treatment.", "quote_or_locator": "Results section 2.1: 'Furthermore, morphine upregulated TLR4 mRNA expression and increased p38 MAPK phosphorylation, both of which were significantly attenuated by zonisamide co-treatment (Figures 1G–I).'"}, {"text": "Male C57BL/6 mice received twice-daily injections of morphine at 10 mg/kg subcutaneously with or without zonisamide for nine consecutive days.", "quote_or_locator": "Results section 2.2: 'To evaluate whether zonisamide prevents the development of chronic morphine tolerance, mice received twice-daily injections of morphine (10 mg/kg, s.c.) with or without zonisamide for nine consecutive days.'"}, {"text": "In the morphine-only group, the antinociceptive effect progressively declined over the treatment period in both the hot-plate and tail-flick tests, indicating the development of analgesic tolerance. Co-administration of zonisamide significantly attenuated this decline.", "quote_or_locator": "Results section 2.2: 'In the morphine-only group, the antinociceptive effect progressively declined over the treatment period in both the hot-plate and tail-flick tests, indicating the development of analgesic tolerance. Co-administration of zonisamide significantly attenuated this decline (Figures 2E,F).'"}, {"text": "Zonisamide did not alter the peak antinociceptive effect of morphine or the area under the curve in either the hot-plate or tail-flick test, indicating that zonisamide does not compromise acute opioid analgesia.", "quote_or_locator": "Results section 2.2: 'As shown in Figures 2A–D, zonisamide did not alter the peak antinociceptive effect of morphine or the area under the curve (AUC) in either the hot-plate or tail-flick test, indicating that zonisamide does not compromise acute opioid analgesia.'"}, {"text": "Pharmacological inhibition of TLR4 with TAK-242 partially recapitulated the protective effect of zonisamide, and no additional benefit was observed when zonisamide was combined with TAK-242.", "quote_or_locator": "Results section 2.2: 'Pharmacological inhibition of TLR4 with TAK-242 (3 mg/kg, i.p.) partially recapitulated the protective effect of zonisamide, and no additional benefit was observed when zonisamide was combined with TAK-242 (Supplementary Figure S3), suggesting that zonisamide's anti-tolerance effect is at least partially dependent on TLR4 signaling.'"}, {"text": "Morphine administration significantly increased Iba1 protein expression in the spinal cord dorsal horn, and this upregulation was markedly suppressed by zonisamide co-treatment.", "quote_or_locator": "Results section 2.3: 'Morphine administration significantly increased Iba1 protein expression, as determined by Western blot analysis, and this upregulation was markedly suppressed by zonisamide co-treatment (Figure 3A).'"}, {"text": "Morphine treatment significantly upregulated TLR4 mRNA expression and increased phosphorylated p38, both of which were significantly attenuated by zonisamide co-treatment in the spinal cord.", "quote_or_locator": "Results section 2.3: 'Morphine treatment significantly upregulated TLR4 mRNA expression and increased the p-p38, both of which were significantly attenuated by zonisamide co-treatment (Figures 4A,B).'"}, {"text": "Morphine-induced increases in the protein levels of IL-1β and TNF-α were significantly reduced by zonisamide in the spinal cord.", "quote_or_locator": "Results section 2.3: 'In addition, morphine-induced increases in the protein levels of IL-1β and TNF-α were significantly reduced by zonisamide (Figures 4C,D).'"}, {"text": "The in vitro experiments were conducted exclusively in the BV-2 microglial cell line, which may not fully recapitulate the responses of primary microglia.", "quote_or_locator": "Discussion: 'First, the in vitro experiments were conducted exclusively in the BV-2 microglial cell line, which may not fully recapitulate the responses of primary microglia. Future validation in primary mouse microglia is warranted.'"}, {"text": "Only a single dose of zonisamide was tested, and experiments were conducted exclusively in male mice; dose-response studies and investigations in female animals are necessary.", "quote_or_locator": "Discussion: 'Second, only a single dose of zonisamide was tested, and experiments were conducted exclusively in male mice; dose-response studies and investigations in female animals are necessary to determine the optimal therapeutic window and assess sex-dependent effects.'"}, {"text": "The lack of cell-type-specific evidence, such as double immunofluorescence staining of Iba1 with TLR4 or p-p38, limits the confirmation that this pathway is specifically activated in spinal microglia.", "quote_or_locator": "Discussion: 'the lack of cell-type-specific evidence, such as double immunofluorescence staining of Iba1 with TLR4 or p-p38, limits the confirmation that this pathway is specifically activated in spinal microglia.'"}, {"text": "A pilot clinical study has demonstrated the safety and tolerability of zonisamide in patients with painful diabetic neuropathy.", "quote_or_locator": "Discussion: 'A pilot clinical study has demonstrated the safety and tolerability of zonisamide in patients with painful diabetic neuropathy (Atli and Dogra, 2005), supporting its feasibility in pain management.'"}], "prompt_version": "p1.0", "verdicts": [{"claim": "In a 2-year prospective cohort of 517 patients receiving stable long-term opioid therapy for musculoskeletal pain, 19.5% underwent dose escalation, but escalation was not associated with improved pain outcomes.", "verdict": "supported", "evidence": "In a 2-year prospective cohort of 517 patients receiving stable long-term opioid therapy for musculoskeletal pain, 19.5% underwent dose escalation, but escalation was not associated with improved pain outcomes (Morasco et al., 2020).", "note": null}, {"claim": "BV-2 microglial cells were treated with morphine at 200 micromolar with or without zonisamide at 10 micromolar for 12 hours.", "verdict": "supported", "evidence": "BV-2 cells were treated with morphine (200 μM) in the presence or absence of zonisamide (10 μM) for 12 h.", "note": null}, {"claim": "Morphine exposure significantly upregulated the mRNA levels of IL-1β, IL-6, and TNF-α, which zonisamide co-treatment markedly suppressed.", "verdict": "supported", "evidence": "Morphine exposure significantly upregulated the mRNA levels of IL-1β, IL-6, and TNF-α, as determined by real-time quantitative PCR. Zonisamide co-treatment markedly suppressed the elevated mRNA expression levels of these pro-inflammatory cytokines (Figures 1A–C).", "note": null}, {"claim": "Zonisamide also significantly reduced morphine-induced protein levels of pro-inflammatory cytokines at the translational level.", "verdict": "supported", "evidence": "ELISA analysis revealed that zonisamide also significantly reduced morphine-induced protein levels of these pro-inflammatory cytokines (Figures 1D–F), confirming that the anti-inflammatory effect of zonisamide occurs at both the transcriptional and translational levels.", "note": null}, {"claim": "Morphine upregulated TLR4 mRNA expression and increased p38 MAPK phosphorylation, both of which were significantly attenuated by zonisamide co-treatment.", "verdict": "supported", "evidence": "Furthermore, morphine upregulated TLR4 mRNA expression and increased p38 MAPK phosphorylation, both of which were significantly attenuated by zonisamide co-treatment (Figures 1G–I).", "note": null}, {"claim": "Male C57BL/6 mice received twice-daily injections of morphine at 10 mg/kg subcutaneously with or without zonisamide for nine consecutive days.", "verdict": "supported", "evidence": "To evaluate whether zonisamide prevents the development of chronic morphine tolerance, mice received twice-daily injections of morphine (10 mg/kg, s.c.) with or without zonisamide for nine consecutive days.", "note": null}, {"claim": "In the morphine-only group, the antinociceptive effect progressively declined over the treatment period in both the hot-plate and tail-flick tests, indicating the development of analgesic tolerance. Co-administration of zonisamide significantly attenuated this decline.", "verdict": "supported", "evidence": "In the morphine-only group, the antinociceptive effect progressively declined over the treatment period in both the hot-plate and tail-flick tests, indicating the development of analgesic tolerance. Co-administration of zonisamide significantly attenuated this decline (Figures 2E,F).", "note": null}, {"claim": "Zonisamide did not alter the peak antinociceptive effect of morphine or the area under the curve in either the hot-plate or tail-flick test, indicating that zonisamide does not compromise acute opioid analgesia.", "verdict": "supported", "evidence": "As shown in Figures 2A–D, zonisamide did not alter the peak antinociceptive effect of morphine or the area under the curve (AUC) in either the hot-plate or tail-flick test, indicating that zonisamide does not compromise acute opioid analgesia.", "note": null}, {"claim": "Pharmacological inhibition of TLR4 with TAK-242 partially recapitulated the protective effect of zonisamide, and no additional benefit was observed when zonisamide was combined with TAK-242.", "verdict": "supported", "evidence": "Pharmacological inhibition of TLR4 with TAK-242 (3 mg/kg, i.p.) partially recapitulated the protective effect of zonisamide, and no additional benefit was observed when zonisamide was combined with TAK-242 (Supplementary Figure S3), suggesting that zonisamide's anti-tolerance effect is at least partially dependent on TLR4 signaling.", "note": null}, {"claim": "Morphine administration significantly increased Iba1 protein expression in the spinal cord dorsal horn, and this upregulation was markedly suppressed by zonisamide co-treatment.", "verdict": "supported", "evidence": "Morphine administration significantly increased Iba1 protein expression, as determined by Western blot analysis, and this upregulation was markedly suppressed by zonisamide co-treatment (Figure 3A).", "note": null}, {"claim": "Morphine treatment significantly upregulated TLR4 mRNA expression and increased phosphorylated p38, both of which were significantly attenuated by zonisamide co-treatment in the spinal cord.", "verdict": "supported", "evidence": "Morphine treatment significantly upregulated TLR4 mRNA expression and increased the p-p38, both of which were significantly attenuated by zonisamide co-treatment (Figures 4A,B).", "note": null}, {"claim": "Morphine-induced increases in the protein levels of IL-1β and TNF-α were significantly reduced by zonisamide in the spinal cord.", "verdict": "supported", "evidence": "In addition, morphine-induced increases in the protein levels of IL-1β and TNF-α were significantly reduced by zonisamide (Figures 4C,D).", "note": null}, {"claim": "The in vitro experiments were conducted exclusively in the BV-2 microglial cell line, which may not fully recapitulate the responses of primary microglia.", "verdict": "supported", "evidence": "First, the in vitro experiments were conducted exclusively in the BV-2 microglial cell line, which may not fully recapitulate the responses of primary microglia. Future validation in primary mouse microglia is warranted.", "note": null}, {"claim": "Only a single dose of zonisamide was tested, and experiments were conducted exclusively in male mice; dose-response studies and investigations in female animals are necessary.", "verdict": "supported", "evidence": "Second, only a single dose of zonisamide was tested, and experiments were conducted exclusively in male mice; dose-response studies and investigations in female animals are necessary to determine the optimal therapeutic window and assess sex-dependent effects.", "note": null}, {"claim": "The lack of cell-type-specific evidence, such as double immunofluorescence staining of Iba1 with TLR4 or p-p38, limits the confirmation that this pathway is specifically activated in spinal microglia.", "verdict": "supported", "evidence": "the lack of cell-type-specific evidence, such as double immunofluorescence staining of Iba1 with TLR4 or p-p38, limits the confirmation that this pathway is specifically activated in spinal microglia.", "note": null}, {"claim": "A pilot clinical study has demonstrated the safety and tolerability of zonisamide in patients with painful diabetic neuropathy.", "verdict": "supported", "evidence": "A pilot clinical study has demonstrated the safety and tolerability of zonisamide in patients with painful diabetic neuropathy (Atli and Dogra, 2005), supporting its feasibility in pain management.", "note": null}]}